Personalized diet- and pharmacotherapy in morbid obesity and metabolic syndrome: A clinical case study

The relevance of this observation is due to the growing problem of morbid obesity and metabolic syndrome, which pose a serious threat to public health worldwide. The case demonstrates the difficulty of managing patients with severe obesity and polymorbidity. The clinical picture of a 60-year-old patient was characterized by morbid obesity (BMI 55.6 kg/m2); metabolic syndrome with type 2 diabetes mellitus, stage III hypertension, dyslipidemia, and fatty hepatosis; cardiovascular disorders with atrial fibrillation, myocardial hypertrophy, pulmonary hypertension; concomitant pathologies: osteoarthritis, chronic pancreatitis, gynecological diseases. The interventions performed included a comprehensive diagnosis of the condition with the involvement of doctors of various specialties, personalized diet therapy and physical therapy, as well as drug therapy with the inclusion of dietary fiber preparations, antihypertensive, hypoglycemic, etc. The outcome of the treatment showed positive dynamics in the form of stabilization of blood pressure, weight loss and improvement of the patient’s general condition. The main conclusions from the presented observation are as follows: the need for a multidisciplinary approach to the treatment of morbid obesity, the importance of personalized diet therapy, the importance of a combination of drug and non-drug treatment, the role of dietary fiber preparation in integrated weight management, the need for long-term patient support to achieve sustainable results. The demonstrated case highlights the complexity of managing patients with morbid obesity and metabolic syndrome, and also demonstrates the effectiveness of an integrated approach while observing all components of diagnosis, treatment, and prevention.

1. GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813–838. https://doi.org/10.1016/S0140-6736(25)00355-1.

2. Noubiap JJ, Nansseu JR, Nyaga UF, Ndoadoumgue AL, Ngouo AT, Tounouga DN et al. Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis. Nat Commun. 2025;17(1):573. https://doi.org/10.1038/s41467-025-67268-5.

3. Balanova YuA, Shalnova SA, Imaeva AE, Kutsenko VA, Kapustina AV, Muromtseva GA et al. Obesity in the Russian population: contribution to survival and cardiovascular events. Data from ESSE-RF and ESSE-RF2. Cardiovascular Therapy and Prevention. 2025;24(6):4336. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4336.

4. Balanova YuA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya AV, Maksimov SA et al. Obesity in the Russian population during the COVID-19 pandemic and associated factors. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S.):3793. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3793.

5. Сhigir AG. Metabolic Syndrome: Current Issues of Diagnosis, Epidemiology and Prevention Worldwide and in the Russian Federation. Epidemiologiya i Vaktsinoprofilaktika. 2025;25(4):95–105. (In Russ.) https://doi.org/10.31631/2073-30462025-24-4-95-105.

6. Матосян КА, Пустовалов ДА, Оранская АН, Мкртумян АМ, Гуревич КГ. Молекулярные основы регуляции пищевого поведения. Molecular Medicine. 2015;(1):18–26. (In Russ.) Available at: https://molmedjournal.ru/ ru/24999490-2015-01-01.

7. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 populationrepresentative studies with 222 million children, adolescents, and adults. The Lancet. 2024;403(10431):1027–1050. https://doi.org/10.1016/S01406736(23)02750-2.

8. Petrenko YV, Gerasimova KS, Novikova VP. Biological and pathophysiological role of adiponectin. Pediatrician (St. Petersburg). 2019;10(2):83–87. (In Russ.) https://doi.org/10.17816/PED10283-87.

9. Alferova VI, Mustafina SV. The role of adipokines in the development of cardiometabolic disorders in humans. Ateroscleroz. 2022;18(4):388–394. (In Russ.) https://doi.org/10.52727/2078-256X-2022-18-4-388-394.

10. Bunenkova GF, Abir EB, Salikova SP, Grinevich VB. Prevalence of liver fibrosis and steatosis in patients with atrial fibrillation. Russian Journal of Cardiology. 2024;29(9S):3. (In Russ.) https://doi.org/10.15829/1560-40712024-9S.

11. Castoldi A, Naffah de Souza C, Câmara NO, Moraes-Vieira PM. The Macrophage Switch in Obesity Development. Front Immunol. 2016;6:637. https://doi.org/10.3389/fimmu.2015.00637.

12. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–563. Available at: https://www.nature.com/articles/nature12820.

13. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014;20(43):16079–16094. https://doi.org/10.3748/wjg.v20.i43.16079.

14. Greiner AK, Papineni RV, Umar S. Chemoprevention in gastrointestinal physiology and disease. Natural products and microbiome. Am J Physiol Gastrointest Liver Physiol. 2014;307(1):11–15. https://doi.org/10.1152/ajpgi.00044.2014.

15. Pyndt Jørgensen B, Hansen JT, Krych L, Larsen C, Klein AB, Nielsen DS et al. A possible link between food and mood: dietary impact on gut microbiota and behavior in BALB/c mice. PLoS ONE. 2014;9(8):e103398. https://doi.org/10.1371/journal.pone.0103398.

16. Ткаченко ЕИ. Питание, микробиоценоз и интеллект человека. СПб.: СпецЛит; 2006. 590 с. Режим доступа: https://www.elibrary.ru/rqdagr.

17. Sutherland JP, Zhou A, Hyppönen E. Muscle traits, sarcopenia, and sarcopenic obesity: a vitamin d mendelian randomization study. Nutrients. 2023;15(12):2703. https://doi.org/10.3390/nu15122703.

18. Feng Z, Xia J, Yu J, Wang J, Yin S, Yang J et al. Pathophysiological Mechanisms Underlying Sarcopenia and Sarcopenic Obesity: A Systematic Review and Meta-Analysis of Biomarker Evidence. Int J Mol Sci. 2025;26(11):5113. https://doi.org/10.3390/ijms26115113.

19. Skvortsova OV, Migacheva NB, Mikhailova EG. Immunometabolic aspects of chronic nonspecific inflammation in obesity. Meditsinskiy Sovet. 2023;17(12):75–82. (In Russ.). https://doi.org/10.21518/ms2023-187.

20. Radchenko VG, Seliverstov PV, Prikhodko EM, SI Sitkin, Ivanyuk ES. Possibilities of clinical application of ursodeoxycholic acid. Vestnik Terapevta. 2022;(1):23–38. (In Russ.) Available at: https://journaltherapy.ru/statyi/ vozmozhnosti-klinicheskogo-primenenija-ursodezoksiholevoj-kisloty.

21. Montanari T, Pošćić N, Colitti M. Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review. Obes Rev. 2017;18(5):495–513. https://doi.org/10.1111/obr.12520.

22. Kurkin DV, Bakulin DA, Morkovin EI, Petrov VI, Strygin AV, Koryanova KN et al. Physiology and pharmacology of glucagon-like peptide-1 receptor. Farmatsiya i Farmakologiya. 2023;11(4):347–380. (In Russ.) https://doi.org/10.19163/2307-9266-2023-11-4-347-380.

23. Laake I, Pedersen JI, Selmer R, Kirkhus B, Lindman A, Tverdal A, Veierød M. A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD. Br J Nutr. 2012;108(4):743–754. https://doi.org/10.1017/S0007114511005897.

24. Downs SM, Thow AM, Leeder SR. The effectiveness of policies for reducing dietary trans fat: a systematic review of the evidence. Bull World Health Organ. 2013;91(4):262–269H. https://doi.org/10.2471/BLT.12.111468.

25. Тутельян ВА, Никитюк ДБ, Аксенов ИВ, Батурин АК, Бессонов ВВ, Воробьева ВМ и др. Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации. М.; 2021. 72 с. Режим доступа: https://www.rospotrebnadzor.ru/upload/iblock/789/1.-mr-2.3.1.0253_21-normy-pishchevykh-veshchestv.pdf.

26. Бурбелло АТ, Гайкова ЛБ, Кухарчик ГА (ред.). Омега­3 полиненасыщенные жирные кислоты в эксперименте и клинической практике. 2-е изд., испр. и доп. СПб.: СЗГМУ им. Мечникова; 2017. 370 с. Режим доступа: https://elibrary.ru/hdwtbs.

27. Дедов ИИ, Мокрышева НГ, Мельниченко ГА, Трошина ЕА, Мазурина НВ, Ершова ЕВ и др. Ожирение: клинические рекомендации. 2024. 71 с. Режим доступа: https://pravo.ppt.ru/rekomendatsiya-rekomendatsii/308635.

28. Salikova SP, Ivanyuk ES. Metabolic syndrome and cardiovascular pathology: focus on non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2020;183(11):62–69. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-183-11-62-69.

29. Komissarenko IA, Levchenko SV. The use of pleiotropic effects of some gastroenterological drugs in the treatment of patients with nonalcoholic fatty liver disease and cardiovascular diseases: A review. Consilium Medicum. 2024;26(12): 868–874. (In Russ.) https://doi.org/10.26442/20751753.2024.12.203090.

30. Guo H, Pan L, Wu Q, Wang L, Huang Z, Wang J et al. Type 2 Diabetes and the Multifaceted Gut-X Axes. Nutrients. 2025;17(16):2708. https://doi.org/10.3390/nu17162708.

31. Zhao X, Qiu Y, Liang L, Fu X. Interkingdom signaling between gastrointestinal hormones and the gut microbiome. Gut Microbes. 2025;17(1):2456592. https://doi.org/10.1080/19490976.2025.2456592.

32. Буденкова ГФ, Гриневич ВБ, Кравчук ЮА. Способ определения наличия фиброза печени по лабораторным показателям и антропометрическим данным. Патент №2849310 C1, 24.03.2025. Режим доступа: https://patents.google.com/patent/RU2849310C1/ru.